“Akorn has recently faced multiple obstacles in the form of increased competition to many of our key products, supply issues, and regulatory and legal challenges,” the US firm’s recently appointed president and chief executive officer, Doug Boothe, acknowledged on his first results call for the ophthalmics and injectables specialist.
Recognizing that there was “a lot of work to be done to return our company to the path of profitable...







